Categories
Change Password!
Reset Password!
New international urticaria guideline advances bio...
Cetirizine among top performers for nasal symptoms...
A large network meta-analysis explored the efficacy and safety of oral H1-antihistamines in allergic rhinitis (AR) by synthesizing evidence from...
Canadian experts update guidance on allergic rhini...
A newly released Canadian-focused practice parameter is reshaping the clinical approach to allergic rhinitis (AR), emphasizing individualized tre...
Role of parental literacy in correct moisturizer a...
Management of atopic dermatitis (AD) in children relies not only on medical treatment but also on parental understanding of the disease.
Long-term dupilumab shows psychological benefits i...
As per the findings of a Phase IV clinical study, long-term treatment with dupilumab can improve emotional functioning in moderate-to-severe atop...
Remibrutinib in CSU: Findings from Phase 3 BISCUIT...
Remibrutinib, a highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, is emerging as a next-generation therapy for the management...
Rapid assessment of chronic spontaneous urticaria...
In chronic spontaneous urticaria (CSU), the weekly urticaria activity score (UAS) is widely used to evaluate disease activity from the patient...
Breastfeeding for ≥4 months linked to lower asthma...
Breastfeeding is widely recognized for its nutritional and immunological benefits, yet its lasting influence on asthma and allergy development in...
Real-world survey exposes treatment challenges in...
A real-world study from the Philippines has uncovered important gaps in the management of allergic rhinitis (AR), showing that many patients cont...
Six-year safety evaluation of upadacitinib in mode...
Atopic dermatitis (AD) is marked by eczematous lesions, severe pruritus, and skin dryness that can hamper quality of life.
